GRPR and neoplasm: Amongst the radiolabeled GRPR-antagonists developed in recent years (Mansi et al. 2021; Nock et al. 2023), [99mTc]Tc-DB15 has especially attracted our attention by combining a high GRPR-affinity, resistance to NEP in the bloodstream, good tumor uptake and excellent tolerability in patients (Nock et al. 2021).